未登录 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database 托珠单抗联合苯达莫司汀和利妥昔单抗治疗方案的安全性分析:利用FDA数据库识别全面的安全性信号 Wu, Fang; Wang, Siliang; Xu, Xihui; Zhang, Weihui; Zhou, Jie; Niu, Runyan; Cai, Wenting; Yang, Yonggong; Liu, Mengying; Zhang, Jinping 分享 收藏
分享 收藏
分享 收藏
分享 收藏
A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS) Zhou, Jie; Zhang, Jinping; Wang, Qiaoyun; Peng, Miaoxin; Qian, Yun; Wu, Fang; Rao, Qi; Laji, DanZhen; Yang, Yonggong; Wang, Siliang; Liu, Mengying 分享 收藏
分享 收藏
FGF12 Positively Regulates Keratinocyte Proliferation by Stabilizing MDM2 and Inhibiting p53 Activity in Psoriasis Wang, Nan; Xu, Xiejun; Guan, Fangqian; Lin, Yifan; Ye, Yizhou; Zhou, Jie; Feng, Jianjun; Li, Sihang; Ye, Junbo; Tang, Zhouhao; Gao, Wenjie; Sun, Bohao; Shen, Yingjie; Sun, Li; Song, Yonghuan; Jin, Litai; Li, Xiaokun; Cong, Weitao; Zhu, Zhongxin 分享 收藏